Atopic Dermatitis

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M

Eli Lilly Reveals More Phase 3 Data From Lebrikizumab Trial In Atopic Dermatitis

VYNE Therapeutics Shares Gain After Positive Atopic Dermatitis Trial Of FMX114

Eli Lilly Reveals More Phase 3 Data From Lebrikizumab Trial In Atopic Dermatitis

VYNE Therapeutics Shares Gain After Positive Atopic Dermatitis Trial Of FMX114

Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis

ASLAN Pharma Kickstarts Mid-Stage Atopic Dermatitis Trial, Data Expected In 2023

Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis

ASLAN Pharma Kickstarts Mid-Stage Atopic Dermatitis Trial, Data Expected In 2023

FDA Approves AbbVie's Upadacitinib For Refractory Atopic Dermatitis In Patients 12 Years & Older

EXCLUSIVE: Hoth Therapeutics Starts Dosing In Second Cohort Of Atopic Dermatitis Trial With BioLexa

Atopic Dermatitis Recent News

Connect Biopharma's Mid-Stage Atopic Dermatitis Trial Meets Primary Endpoint

AbbVie Presents New Upadacitinib Data In Atopic Dermatitis

Pfizers' JAK Inhibitor Approved In Japan For Atopic Dermatitis

Why Did ASLAN Pharma Shares Plunge Despite Positive Atopic Dermatitis Trial Data?

Incyte's Topical JAK Inhibitor Scores FDA Approval For Atopic Dermatitis

The FDA has approved Incyte Corporation's (NASDAQ: INCY) Opzelura (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD).

Pfizer's Abrocitinib Beats Dupixent Late-stage Eczema Trial

Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis

Lilly's Lebrikizumab Shows Clinical Benefit In Late-Stage Atopic Eczema Trials

VYNE Therapeutics Stock Drops On Potential Sale Of Topical Minocycline Franchise

FDA Will Not Meet Goal Dates For Pfizer's Xeljanz, Abrocitinib Applications

AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA

AbbVie Inc (NYSE: ABBV) and Eli Lilly And Co (NYSE: LLY) will have to keep waiting for a chance for their JAK inhibitors in atopic dermatitis to see the market.

RAPT Therapeutics Stock Soars As Atopic Dermatitis Candidate Shows Promising Action In Early-Stage Study

Aclaris' ATI-1777 Aces Atopic Dermatitis Trial with Minimal Systemic Exposure

Cara Therapeutics' Stock Plummets As Korsuva Flunks In Mid-Stage Atopic Dermatitis Study

Incyte Announces New Ruxolitinib Data From Atopic Dermatitis and Vitiligo Studies

Kindred's New IL-31 Antibody Shows Improved Shelf Life In PK Study For Canine Dermatitis

AbbVie's Upadacitinib US Application Review In Atopic Dermatitis Postponed

Aslan Pharmaceuticals Shares Are Trading Higher On Positive ASLAN004 Data In Atopic Dermatitis

Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) announces positive interim unblinded data from its ongoing Phase 1 study evaluating ASLAN004 to treat moderate to severe ato

Sanofi/Regeneron's DUPIXENT Wins Canada Approval For Atopic Dermatitis In Children Aged 6-11

FDA Accepts Incyte's Ruxolitinib Cream US Application For Chronic Skin Disease

Expectations For Regeneron No Longer Realistic; Analyst Downgrades

Anacor Shares Surge To All-Time Highs After Phase 3 Trials Of Eczema Drug